Medpace (MEDP) closed the latest trading day at $339.38, indicating a +1.08% change from the previous session's end. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. Shares of the provider of outsourced clinical development services have depreciated by 13.17% over the course of the past month, underperforming the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. Analysts and investors alike will be keeping a close e ...

Core Insights - Medpace Holdings (NASDAQ:MEDP) stock has increased by 69% since the buy rating was issued in January 2023, confirming the initial investment thesis from July 2022 [5] - The company demonstrates strong profitability with a return on invested capital (ROIC) of over 33%, driven by 16% NOPAT margins and a capital turnover of approximately 2.4x [5][8] - Free cash flow (FCF) generation has been robust, ranging from $200 million to $500 million annually since FY'21, with minimal incremental capital employed [5][8] - The company has a solid backlog of approximately $2.9 billion, reflecting a year-over-year increase of 13.7% [10][12] - Management has revised FY24 sales guidance to between $2.125 billion and $2.175 billion, indicating a top-line growth of 13% to 15.3% year-over-year [8][12] Financial Performance - Q2 FY'24 revenues reached $28.1 million, marking a 14.6% year-over-year increase, with year-to-date sales totaling $1.04 billion, up 16.1% year-over-year [8][12] - EBITDA for Q2 is projected between $430 million and $460 million, reflecting a growth of 27% at the upper end, with earnings per share estimated at $11.93 [8][12] - The net new business awards decreased by 4.1% year-over-year to $551 million, with a net book-to-bill ratio of 1.04, indicating a healthy but slightly declining trend [9][12] Valuation and Growth Potential - The intrinsic value of MEDP is estimated to exceed $400 per share, supported by a compounding growth rate of 5% in intrinsic value and a potential reinvestment of 15% of cumulative NOPAT at 20-30% incremental returns [19][22] - The company has maintained a high ROIC, which is expected to attract higher EV/IC multiples, enhancing its market valuation [16][22] - Future projections indicate that economic earnings could reach approximately $287.34 million in FY'24, with a per-share value of $9.33 [25]

Core Viewpoint - Medpace Holdings, Inc. has faced significant stock price decline following disappointing second quarter 2024 financial results, raising concerns about potential violations of federal securities laws and unlawful business practices [2][1]. Financial Performance - On July 22, 2024, Medpace reported second quarter 2024 financial results that significantly missed market expectations [2]. - The company experienced disproportionately high cancellations in June 2024, attributed to factors such as reprioritization, impaired sponsor liquidity, and a large pharmaceutical acquisition that led to work being shifted to a preferred provider [2]. Stock Market Reaction - Following the earnings announcement, Medpace's stock price dropped by $79.88, or 18.3%, closing at $357.30 per share on July 23, 2024, resulting in losses for investors [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Medpace on behalf of its stockholders regarding possible violations of federal securities laws and other unlawful business practices [1].

SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Medpace Holdings, Inc. (NASDAQ: MEDP) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/MEDP Contact the Firm Now: MEDP@hbsslaw.com 844-916-0895 Medpace Holdings, Inc. (MEDP) Investigation: Medpace Holdings, Inc. is facing scrutiny over its recent financial perform ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. Medpace (MEDP) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. While the historical EPS growth rate for Medpace is 32.2%, investors should actually focus o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 _________________________ ...

| --- | --- | |-------|-------| | | | | | | | | | This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking state ...

2024 Financial Guidance To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. Forward-Looking Statements These and other important factors discussed under ...

During the first quarter of 2024, Medpace witnessed a robust revenue uptick year over year on the back of a strong backlog conversion rate. Its net new business awards were also strong during the period. We expect the company to have continued to register strong backlog addition in the second quarter. On its first-quarter earnings call in April, the company projected backlog conversion of approximately $1.56 billion to revenues in 12 months. This is likely to have reflected in the second-quarter result. Cen ...

The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 22, 2024, Medpace reported EPS of $3.2 versus consensus estimate of $2.45 while it missed the consensus revenue estimate by 0.33%. Medpace may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is ...